Xenetic Biosciences
Biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens.
Launch date
Employees
Market cap
$6.2m
Enterprise valuation
($1m) (Public information from Sep 2024)
Share price
$3.65 XBIO
Company register number 03213174
London England (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | 1.1m | 1.6m | 2.3m | 2.0m | 1.7m | 2.1m |
| % growth | 2460 % | 166 % | 47 % | 49 % | (12 %) | (18 %) | 28 % |
| EBITDA | 4.2m | (5.2m) | (6.1m) | (4.1m) | (5.7m) | (8.7m) | (14.1m) |
| % EBITDA margin | 1048 % | (492 %) | (392 %) | (178 %) | (282 %) | (522 %) | (665 %) |
| Profit | (9.9m) | (5.1m) | (6.0m) | (3.8m) | (5.5m) | (8.4m) | (13.9m) |
| % profit margin | (2493 %) | (486 %) | (384 %) | (163 %) | (273 %) | (505 %) | (652 %) |
| EV / revenue | 39.5x | 14.5x | 2.8x | 2.2x | 2.8x | 3.5x | 2.7x |
| EV / EBITDA | 3.8x | -3.0x | -0.7x | -1.2x | -1.0x | -0.7x | -0.4x |
| R&D budget | 1.6m | 2.9m | 4.3m | 3.2m | - | - | - |
| R&D % of revenue | 396 % | 273 % | 279 % | 138 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$10.0m | Early VC | ||
| Total Funding | $10.0m | ||
Related Content
Recent News about Xenetic Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.